Oncolytic adenovirus-mediated short hairpin RNA targeting MYCN gene induces apoptosis by upregulating RKIP in neuroblastoma

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Yuan LiJunnian Zheng

Abstract

The amplification of MYCN is a typical characteristic of aggressive neuroblastomas, whereas acquired mutations of p53 lead to refractory and relapsed cases. We had previously examined the applicability of the replication-competent oncolytic adenovirus, ZD55-shMYCN, to deliver a short hairpin RNA targeting MYCN gene for p53-null and MYCN-amplified neuroblastoma cell line LA1-55N. Our data have shown that ZD55-shMYCN has an additive tumor growth inhibitory response through shRNA-mediated MYCN knockdown and ZD55-mediated cancer cell lysis. In this regard, ZD55-shMYCN can downregulate MYCN and perform anticancer effects, thereby acquiring significance in the administration of MYCN-amplified and p53-null neuroblastomas. Hence, we further investigated the anticancer properties of ZD55-shMYCN in neuroblastomas. Our data showed that ZD55-shMYCN induced G2/M arrest via decreasing the levels of cyclin D1 and cyclin B1 irrespective of p53 status. ZD55-shMYCN effectively induced apoptosis in neuroblastomas through activation of caspase-3 and enhancing PARP cleavage. Furthermore, ZD55-shMYCN could downregulate phosphoinositide 3-kinase and pAkt and upregulate RKIP levels. Similarly, pro-apoptosis was revealed by the histopathologic examinat...Continue Reading

References

Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·S A InnocenteJ M Lee
Jun 24, 1999·The New England Journal of Medicine·R P Castleberry
Dec 28, 1999·Annual Review of Cell and Developmental Biology·I BudihardjoX Wang
Mar 22, 2003·Current Opinion in Cell Biology·Dennis W Stacey
Mar 26, 2003·Journal of Molecular Biology·Dag R SørensenMouldy Sioud
May 3, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·Karoly TothWilliam S M Wold
Dec 31, 2003·Gene·Max M van Noesel, Rogier Versteeg
Feb 10, 2004·The Journal of Biological Chemistry·Devasis ChatterjeeKam C Yeung
Jul 9, 2004·Nature·Carl D Novina, Phillip A Sharp
Aug 3, 2004·Cancer Gene Therapy·Eugene Lin, John Nemunaitis
Feb 3, 2005·Cell Research·Nicholas Trakul, Marsha R Rosner
Nov 22, 2005·Oncogene·Manish Aghi, Robert L Martuza
Oct 24, 2006·Biochemical and Biophysical Research Communications·Jung-Hee KangDai H Chung
Nov 15, 2006·Cell Research·Xin Yuan Liu
Jun 10, 2008·Current Pharmaceutical Design·Qi Zhao WangRuian Xu
Jan 21, 2009·The EMBO Journal·Surabhi Dangi-GarimellaMarsha Rich Rosner
May 9, 2009·Advanced Drug Delivery Reviews·Yu-Kyoung Oh, Tae Gwan Park
Dec 4, 2009·Developmental Neuroscience·Julian HellmannCatrin Wernicke
Mar 18, 2011·Cancer Prevention Research·Jyotsana SinghalSanjay Awasthi
Sep 18, 2013·Anti-cancer Agents in Medicinal Chemistry·Alicia M Waters, Elizabeth A Beierle
Nov 12, 2013·British Medical Bulletin·Lucas MorenoAndrew D J Pearson

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.